A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

• ClinicalTrials.gov Identifier: NCT01975519
• Recruitment Status: Completed
• First Posted: November 3, 2013
• Results First Posted: May 12, 2020
• Last Update Posted: May 20, 2020
• Sponsor: Tracon Pharmaceuticals Inc.
• Information provided by (Responsible Party): Tracon Pharmaceuticals Inc.

Study Description

Brief Summary:

The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. Up to 30 patients will be treated.

The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1 and estimate ORR in a separate cohort of patients with angiosarcoma by RECIST 1.1. Up to 89 patients will be treated in phase 2, including two cohorts of up to 13 patients with angiosarcoma.

Condition or disease	Intervention/treatment	Phase
Advanced Soft Tissue Sarcoma	Drug: TRC105 and Pazopanib	Phase 1; Phase 2

Detailed Description:

Pazopanib is an oral inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. Pazopanib is approved for the treatment of advanced soft tissue sarcoma, following progression on one prior systemic therapy, based on improved progression free survival. TRC105 is an antibody to CD105, an important angiogenic target on vascular endothelial cells that is distinct from VEGFR. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models and complements the activity of bevacizumab and multi-kinase inhibitors that target the VEGFR. In a phase 1 study of advanced solid tumors, TRC105 therapy caused a global reduction in angiogenic biomarkers and reduced tumor burden at doses that were well-tolerated. In a phase 1b study, the combination of TRC105 and bevacizumab produced radiographic reductions in tumor volume in bevacizumab-refractory patients, and was well tolerated. TRC105 potentiates bevacizumab and VEGFR tyrosine kinases (VEGFR TKI) in preclinical models. By targeting a non-VEGF pathway that is upregulated following VEGF inhibition, TRC105 has the potential to complement VEGFR TKIs and could represent a major advance in cancer therapy. Together, the use of TRC105 with pazopanib may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with pazopanib alone.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 111 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
• Actual Study Start Date: December 10, 2013
• Actual Primary Completion Date: March 11, 2019
• Actual Study Completion Date: March 11, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: TRC105 and Pazopanib; Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.	Drug: TRC105 and Pazopanib; Weekly TRC105 in combination with standard dose Pazopanib.; Other Names: Chimeric Antibody (TRC105) to CD105; Votrient

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Dose Limiting Toxicity (DLT) [ Time Frame: 56 days ]
   For DLT evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0). DLTs were defined as grade 4 neutropenia persisting for ≥ 5 days, febrile neutropenia (grade 4 neutropenia with fever > 38.5 ºC both sustained over a 24 hour period), neutropenic infection (grade ≥ 3 neutropenia with grade ≥ 3 infection), anemia ≥ grade 4, grade > 4 thrombocytopenia or grade ≥ 3 thrombocytopenia and grade ≥ 3 hemorrhage, or grade 3 or 4 nonhematologic toxicity with the following exceptions: nausea, vomiting, or diarrhea for <48 hours, asymptomatic electrolyte abnormalities that are corrected to grade 1 or better in < 72 hours, or headache lasting less than 48 hours.
2. Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) [ Time Frame: from screening to either disease progression or death ]
   Number of patients with progression free survival, as defined as time from screening to either first disease progression or death from any cause per RECIST version 1.1
3. Objective Response Rate in a Cohort of Patients With Angiosarcoma [ Time Frame: 1.5 years ]
   The best response according to RECIST 1.1 for each patient in the phase 2 angiosarcoma cohort with measurable disease and who received at least one dose of study drug will be listed by cohort and tumor type

Secondary Outcome Measures :

1. Trough Concentrations of TRC105 (Phase 2) [ Time Frame: 4, 6, 8, and 10 weeks ]
   Trough serum TRC105 concentrations will be measured using validated ELISA methods.
2. Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) [ Time Frame: 32 months ]
   Anti-product antibody concentrations will be measured using validated ELISA methods. Anti-product antibody concentrations will be evaluated in the context of pharmacokinetic parameters and AE profiles.
3. Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2) [ Time Frame: 12 months ]
   Expression will be determined by immunohistochemistry for each patient who received at least one dose of TRC105
4. Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 [ Time Frame: 12 months ]
   The best response (CR, PR, SD or PD according to RECIST 1.1) for each patient (phase 1 and phase 2) with measurable disease who received at least one dose of TRC105 study drug
5. Progression Free Survival in a Cohort of Patients With Angiosarcoma (Phase 2) [ Time Frame: 26 months ]
   Time from screening to either first disease progression or death from any cause per RECIST version 1.1

Eligibility Criteria

• Ages Eligible for Study: 12 Years to 120 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically confirmed unresectable soft tissue sarcoma that has progressed following treatment with chemotherapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity ( Phase 1b only)
2. Histologically confirmed metastatic soft tissue sarcoma that has progressed by RECIST following treatment with anthracycline chemotherapy. Patients may have received up to four lines of systemic therapy for metastatic disease and no more than two lines of combination treatment ( Phase 2 only)
3. Histologically confirmed locally advanced (e.g. unresectable) or metastatic angiosarcoma that has progressed following treatment with prior systemic therapy. Progression must be documented on or following the most recent systemic therapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity (Phase 2 angiosarcoma cohorts only)
4. Measurable disease by RECIST
5. Age of 12 years or older (patient must weigh ≥ 40 kg)
6. ECOG performance status ≤ 1
7. Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia or neuropathy)
8. Adequate organ function.
9. Willingness and ability to consent for self to participate in study
10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
11. Available archival tumor specimen of the soft tissue sarcoma that meets inclusion criterion #1, #2 or #3

Exclusion Criteria:

1. Prior treatment with TRC105
2. Prior treatment with a VEGFR TKI (including pazopanib) (Phase 2 only)
3. Current treatment on another therapeutic clinical trial
4. Receipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment.
5. No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months.
6. Patients who have received wide field radiotherapy ≤ 28 days or limited field radiation for palliation < 14 days prior to cycle 1 day 1 or those patients who have not recovered adequately from side effects of such therapy
7. Uncontrolled chronic hypertension
8. Significant ascites or pericardial or pleural effusion
9. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease.
10. Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.
11. Active bleeding or pathologic condition that carries a high risk of bleeding. Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible.
12. Thrombolytic use (except to maintain i.v. catheters) within 10 days prior to first day of study therapy
13. Known active viral or nonviral hepatitis or cirrhosis
14. History of hemorrhage or hemoptysis within 3 months of starting study treatment
15. History of peptic ulcer within the past 3 months of treatment
16. History of gastrointestinal perforation or fistula in the past 6 months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved
17. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
18. Receipt of a strong CYP3A4 inducer within 12 days prior to cycle 1 day 1 or a strong CYP3A4 inhibitor within 7 days prior to cycle 1 day 1.
19. Pregnancy or breastfeeding. Female patients must be surgically sterile (i.e.: hysterectomy) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to first dose. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate.
20. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.

Contacts and Locations

Locations

United States, Alabama

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35243

United States, California

Sarcoma Oncology Center

Santa Monica, California, United States, 90403

United States, Florida

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

United States, Minnesota

Mayo Clinic Rochester

Rochester, Minnesota, United States, 55905

United States, New York

Roswell Park Cancer Institute

Buffalo, New York, United States, 92122

Mount Sinai School of Medicine-Tisch Cancer Institute

New York, New York, United States, 10029

United States, North Carolina

Duke University

Durham, North Carolina, United States, 27710

United States, Texas

Mary Crowley Cancer Research Center

Dallas, Texas, United States, 75230

United States, Utah

University of Utah

Salt Lake City, Utah, United States, 84112

Sponsors and Collaborators

Tracon Pharmaceuticals Inc.

Investigators

• Study Director: Charles Theuer, MD; Tracon Pharmaceuticals Inc.

  Study Documents (Full-Text)

Documents provided by Tracon Pharmaceuticals Inc.:

Study Protocol and Statistical Analysis Plan  [PDF] July 22, 2016

More Information

• Responsible Party: Tracon Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT01975519
• Other Study ID Numbers: 105SAR101
• First Posted: November 3, 2013
• Results First Posted: May 12, 2020
• Last Update Posted: May 20, 2020
• Last Verified: May 2020

Keywords provided by Tracon Pharmaceuticals Inc.:

TRC105; CD105; Endoglin; Angiogenesis Inhibitor; STS; Soft Tissue Sarcoma; TKI; Tyrosine Kinase Inhibitor; Pazopanib; Votrient; Advanced Soft Tissue Sarcoma; Angiosarcoma

Additional relevant MeSH terms:

Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Antibodies, Monoclonal; Immunologic Factors; Physiological Effects of Drugs